Introduction

Lung cancer is one of the most prevalent forms of cancer to afflict both men and women and is thought to account for approximately 15% of all cancer cases. In 2002, approximately 376,000 patients are expected to die from lung cancer in the 7 major pharmaceutical markets, and this figure is expected to increase to 403,000 by 2007. The report provides detailed analyses of the current treatment standards, and profiles marketed and key pipeline drugs for lung cancer, with sales forecasts to 2010. 

Scope

Results of extensive physician research across the seven major markets: US, Japan, Germany, France Italy, Spain and UK 

Main treatment regimens in first- and second-line in the 7 major markets 

Physicians’ opinion on the role of taxanes in the treatment of lung cancer 

Profiles and potential of key drugs in development for lung cancer 

Sales forecasts to 2010 

Report Highlights

Taxol’s impending EU patent expiry is likely to slow the growth of Taxotere as first-line NSCLC therapy.

Reasons to Purchase

Identify the key regimens used for first-and second-line treatment of NSCLC and SCLC in the seven major markets 

Determine the pricing level of your product by assessing the cost analysis of common regimens for lung cancer 

Evaluate key drugs in late-stage development for lung cancer to enhance your commercial positioning of your product 

Predict the future potential of key pipeline drugs for lung cancer by analyzing the sales forecast for these drugs to 2010 

Report Highlights

Cisplatin continues to dominate anti-lung cancer platinum agents. However, BMS’ aggressive marketing has preserved Paraplatin’s gold-standard status in the US. 

AstraZeneca’s Iressa is expected to generate lower sales than originally anticipated. Datamonitor believes the mantle of the lung cancer market driver is expected to fall on Isis’ Affinitac. 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a301